EIF2B5: A Drug Target and Biomarker for Eukaryotic Translation Initiation

Target Name: EIF2B5

NCBI ID: G8893

EIF2B5

EIF2B5: A Drug Target and Biomarker for Eukaryotic Translation Initiation

Eukaryotic translation initiation factor 2B (EIF2B) is a protein that plays a crucial role in the initiation of protein translation from mRNA to protein. It is a key component of the translation machinery and is highly expressed in various tissues and cells. However, despite its importance, the function and regulation of EIF2B remain poorly understood.

Recent studies have identified potential drug targets and biomarkers for EIF2B. One such study identified EIF2B5, a unique isoform of EIF2B, as a potential drug target due to its unique structure and function. In this article, we will discuss the role of EIF2B5 as a drug target and biomarker, as well as its potential clinical applications.

The Role of EIF2B in Protein Translation

EIF2B is a protein that consists of two subunits: EIF2B伪 and EIF2B尾. EIF2B伪 is the N-terminus of the protein and is responsible for interacting with the mRNA, while EIF2B尾 is the C-terminus and is responsible for interacting with the translation machinery.

EIF2B is involved in the initiation of protein translation by helping to establish a complex between the mRNA and the ribosome. This complex is formed through the interaction of the amino acids that make up the protein and the RNA. Once the complex is formed, the ribosome begins reading the mRNA sequence and initiates the translation process.

The regulation of EIF2B is critical for the proper function of the translation machinery. Many studies have shown that changes in the level or activity of EIF2B can affect protein translation efficiency. For example, studies have shown that overexpression of EIF2B can enhance protein translation, while inhibition can reduce translation efficiency.

Drug Targeting EIF2B5

Recent studies have identified EIF2B5 as a potential drug target due to its unique structure and function. EIF2B5 is a unique isoform of EIF2B that is expressed in various tissues and cells, including the brain, heart, and liver. It is characterized by a unique N-terminus that includes a unique domain and a unique C-terminus that includes a unique extension.

One of the unique features of EIF2B5 is its ability to interact with the protein kinase PDK4. PDK4 is a protein that is involved in the regulation of many cellular processes, including cell growth, differentiation, and survival. Studies have shown that EIF2B5 can interact with PDK4 and that this interaction may play a role in the regulation of protein translation.

In addition to its interaction with PDK4, EIF2B5 has also been shown to interact with several other proteins, including the transcription factor NF-kappa-B. This interaction between EIF2B5 and NF-kappa-B may be involved in the regulation of gene expression and protein translation.

Biomarker Potential

The potential use of EIF2B5 as a biomarker for various diseases has been identified. For example, EIF2B5 has been shown to be expressed in various types of cancer, including breast, ovarian, and prostate cancer. This suggests that EIF2B5 may be a useful biomarker for cancer diagnosis and treatment.

In addition to its potential as a biomarker, EIF2B5 has also been shown to be involved in the regulation of cellular processes, including cell growth, differentiation, and survival. This suggests that EIF2B5 may be a useful target for drugs that are aimed at modulating these processes.

Clinical Applications

The potential use of EIF2B5 as a drug target and biomarker has led to a growing interest in its use in the development of new pharmaceuticals.

Protein Name: Eukaryotic Translation Initiation Factor 2B Subunit Epsilon

Functions: Catalyzes the exchange of eukaryotic initiation factor 2-bound GDP for GTP

The "EIF2B5 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about EIF2B5 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets